Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial

Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative have provided an enrollment update for the (Z)-Endoxifen arm of the ongoing I-SPY 2 clinical trial. Six patients have been dosed with Atossa's proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, which is being evaluated as a neoadjuvant treatment for patients with newly diagnosed estrogen receptor-positive i..